Celeste Mullins
Family · Big Stone Gap, VANPI 1922437011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,938 of the $53,190 with a category attached, or 92.0%. AbbVie accounts for 95.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $38,324 and has fallen 93.6% since, to $2,444 in 2025. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $234.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$51K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$617
- Alkermes, Inc.$428
- Axsome Therapeutics, Inc.$213
- Neurocrine Biosciences, Inc.$208
- E.r. Squibb & Sons, L.L.C.$200
- plus $786 from 7 others
What the payments were for
- Speaking & faculty fees$48,93892%
- Travel & lodging$7311%
- Food & beverage$3,4156%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 139 | $50,738 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $617 |
| Alkermes, Inc. | 10 | $428 |
| Axsome Therapeutics, Inc. | 5 | $213 |
| Neurocrine Biosciences, Inc. | 11 | $208 |
| E.r. Squibb & Sons, L.L.C. | 5 | $200 |
| Vanda Pharmaceuticals Inc. | 4 | $200 |
| Otsuka America Pharmaceutical, Inc. | 10 | $173 |
| 3b Medical, Inc. | 1 | $149 |
| AstraZeneca | 1 | $125 |
| Lundbeck LLC | 5 | $66 |
| Johnson & Johnson | 2 | $45 |
| Astellas Pharma US Inc | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,190 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 140 | $422,332 |
| VraylarCariprazine Hcl | 218 | $320,389 |
| IngrezzaValbenazine Tosylate | 28 | $236,004 |
| RexultiBrexpiprazole | 46 | $67,751 |
| AristadaAripiprazole Lauroxil | 20 | $51,038 |
| CaplytaLumateperone Tosylate | 30 | $50,059 |
| TrintellixVortioxetine Hydrobromide | 86 | $46,277 |
| Risperdal ConstaRisperidone Microspheres | 11 | $14,813 |
| Lurasidone Hcl | 59 | $10,362 |
| FetzimaLevomilnacipran Hcl | 17 | $8,518 |
| Clozapine | 111 | $7,206 |
| Ziprasidone Hcl | 101 | $6,675 |
| Divalproex Sodium ErDivalproex Sodium | 182 | $6,373 |
| Trazodone Hcl | 546 | $5,070 |
| Paliperidone ErPaliperidone | 45 | $4,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Invega | $45 | $440,952162 claims |
| AbbVieVraylar, Fetzima | $50,738 | $328,907235 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $208 | $236,00428 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $173 | $67,75146 claims |
| Alkermes, Inc.Aristada | $428 | $51,03820 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $617 | $50,05930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Big Stone Gap
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.